Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINFOL-05: Rina-S in Non-Small Cell Lung Cancer
jRCT2041250176Phase 2Recruiting
- Sponsor
- Genmab
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rinatabart sesutecan in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Genmab. Primary endpoint: Objective response rate (ORR). Started Apr 2026; status: recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT2041250176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250176.